Results 111 to 120 of about 22,676 (187)

Neuroprotective effects of melatonin and calpeptin in a rat model of focal cerebral ischemia [PDF]

, 2014
Introduction: Melatonin is a potent-free radical scavenger and antioxidant. Previously, we have demonstrated beneficial effects of pretreatment with melatonin in mild and severe focal cerebral ischaemia in rodent models.
Cheung, RTF, Feng, Y
core  

Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study

Journal of Pharmaceutical Health Care and Sciences
Background 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) and dexamethasone are recommended to prevent azacitidine-induced nausea and vomiting. In clinical practice, 5-HT3RAs or metoclopramide is often used without dexamethasone. In this study, we
Yoshinori Wakasugi, Yoshito Ikeda, Satoshi Noda, Makoto Murata, Shin-ya Morita   +4 more
doaj   +1 more source

Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia [PDF]

, 2015
Jakšić, Ozren, Kušec, Rajko, Lasan-Trčić, Ružica, Lucijanić, Marko, Pejša, Vlatko, Štoos-Veić, Tajana   +5 more
core   +1 more source

Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma [PDF]

, 2017
Bartlett, Nancy L, et al,, Ghobadi, Armin   +2 more
core   +2 more sources

Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report. [PDF]

SAGE Open Med Case Rep
Benallaoua K, Lacoeuilhe P, Gendrot B, Muhammad S, Fouquet G.   +4 more
europepmc   +1 more source

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions. [PDF]

J Pers Med
Ko KH, Gelfer R, Wheat JC, Cai SF.
europepmc   +1 more source

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. [PDF]

Blood Adv
Sekeres MA, Mattison R, Artz A, Baer MR, Chua CC, Demichelis-Gómez R, Egan PC, Fletcher L, Foucar C, Garcia JS, Gilberto L, Gómez de León A, Lancet J, Loh KP, Malcovati L, Marini B, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt G, Brignardello-Petersen R.   +24 more
europepmc   +1 more source

Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid. [PDF]

Int J Mol Sci
Harrer DC, Lüke F, Pukrop T, Reichle A, Heudobler D.   +4 more
europepmc   +1 more source

Acute Myeloid Leukemia in the Elderly Patient: New Strategies [PDF]

, 2015

core   +1 more source

Does age matter? Optimizing AML treatment in older adults. [PDF]

Blood Adv
Lai C, Lin TL.
europepmc   +1 more source